Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of Saturday, July 25, 2026.
Forward PE Ratio (N/A) = Close Price ($89.33) / Consensus Forward EPS ($-4.50)
FORWARD PE RATIO
N/A
BioNTech SE
Market Cap
$22.59B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| BioNTech SE (BNTX) | $22.59B | N/A |
| United Therapeutics Corporation (UTHR)vs › | $22.43B | 18.97 |
| West Pharmaceutical Services, Inc. (WST)vs › | $23.10B | 37.25 |
| Incyte Corporation (INCY)vs › | $23.51B | 15.25 |
| Moderna, Inc. (MRNA)vs › | $21.45B | N/A |
| STERIS plc (STE)vs › | $20.86B | 20.99 |
| Labcorp Holdings Inc. (LH)vs › | $24.34B | 16.47 |
| Waters Corporation (WAT)vs › | $24.42B | 25.80 |
| Viatris Inc. (VTRS)vs › | $20.08B | 7.03 |
| Quest Diagnostics Incorporated (DGX)vs › | $25.15B | 20.67 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus next-FY EPS
At today's $89.33 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-4.50 | $-4.73 – $-4.26 | 9 | n/m |
| 2027-12-31 | $-4.72 | $-6.18 – $-3.26 | 8 | n/m |
| 2028-12-31 | $-4.41 | $-9.44 – $-0.70 | 13 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
